Pyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pyxis Oncology (NASDAQ:PYXS) from a sell rating to a hold rating in a research report released on Saturday.

A number of other equities analysts also recently weighed in on PYXS. Stifel Nicolaus started coverage on Pyxis Oncology in a research report on Monday, November 3rd. They set a “buy” rating and a $9.00 price target for the company. Guggenheim increased their price target on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. HC Wainwright raised their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Royal Bank Of Canada reduced their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Stock Performance

Pyxis Oncology stock opened at $1.76 on Friday. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55. The business’s fifty day moving average is $3.09 and its two-hundred day moving average is $2.42. The firm has a market cap of $109.58 million, a P/E ratio of -1.10 and a beta of 1.44.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. On average, equities research analysts predict that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE boosted its stake in shares of Pyxis Oncology by 2,690.9% during the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock valued at $1,367,000 after buying an additional 593,853 shares during the last quarter. Longaeva Partners L.P. acquired a new stake in Pyxis Oncology in the 3rd quarter valued at about $1,117,000. Citadel Advisors LLC acquired a new position in shares of Pyxis Oncology in the 3rd quarter valued at $749,000. Jane Street Group LLC acquired a new stake in Pyxis Oncology during the 2nd quarter valued at $370,000. Finally, Schulhoff & Co. Inc. increased its stake in Pyxis Oncology by 125.4% in the 2nd quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock valued at $302,000 after buying an additional 153,000 shares during the period. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.